{"id":476978,"date":"2018-05-17T10:23:25","date_gmt":"2018-05-17T14:23:25","guid":{"rendered":"https:\/\/www.sciencedaily.com\/releases\/2018\/05\/180517102325.htm"},"modified":"2018-05-17T10:23:25","modified_gmt":"2018-05-17T14:23:25","slug":"shorter-trastuzumab-treatment-for-her2-breast-cancer-can-be-as-effective-with-fewer-cardiac-side-effects","status":"publish","type":"post","link":"https:\/\/spaceweekly.com\/?p=476978","title":{"rendered":"Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects"},"content":{"rendered":"<p>A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months. The disease-free survival rate at four years was 89.4 percent with 6 months of therapy and 89.8 percent with 12 months of therapy. In addition, only 4 percent of women in the 6-month arm stopped trastuzumab early because of cardiac problems, compared with 8 percent in the 12-month arm. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months. The disease-free survival rate at four year&#8230;<\/p>\n","protected":false},"author":61,"featured_media":615444,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-476978","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts\/476978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/users\/61"}],"replies":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=476978"}],"version-history":[{"count":1,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts\/476978\/revisions"}],"predecessor-version":[{"id":476979,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts\/476978\/revisions\/476979"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/media\/615444"}],"wp:attachment":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=476978"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=476978"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=476978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}